Anika Therapeutics, Inc.
ANIK
$14.36
$0.161.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.91% | 30.55% | 16.51% | 4.61% | -0.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.91% | 30.55% | 16.51% | 4.61% | -0.73% |
| Cost of Revenue | 13.18% | 124.11% | 71.92% | 34.66% | 13.18% |
| Gross Profit | -16.71% | -2.41% | -5.70% | -8.08% | -7.18% |
| SG&A Expenses | -11.64% | 68.73% | 25.23% | 11.23% | -7.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.43% | 86.40% | 43.92% | 22.11% | 3.71% |
| Operating Income | -145.85% | -160.31% | -167.99% | -157.60% | -632.58% |
| Income Before Tax | -236.72% | -144.63% | -149.44% | -135.60% | -187.58% |
| Income Tax Expenses | -88.92% | -66.37% | -45.11% | -26.40% | -8.05% |
| Earnings from Continuing Operations | -13.04% | -244.31% | -350.94% | -318.57% | -156.70% |
| Earnings from Discontinued Operations | 98.11% | 33.38% | -45,319.05% | -1,694.92% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.70% | 66.12% | 18.27% | 26.14% | 31.79% |
| EBIT | -145.85% | -160.31% | -167.99% | -157.60% | -632.58% |
| EBITDA | -558.59% | -132.66% | -127.68% | -107.09% | -81.21% |
| EPS Basic | 80.25% | 65.67% | 18.14% | 26.12% | 31.95% |
| Normalized Basic EPS | -345.16% | -144.32% | -146.56% | -131.63% | -167.81% |
| EPS Diluted | 79.86% | 65.52% | 17.95% | 26.12% | 32.04% |
| Normalized Diluted EPS | -344.07% | -144.12% | -146.28% | -131.63% | -167.81% |
| Average Basic Shares Outstanding | -2.60% | -2.21% | -1.40% | -0.33% | 0.43% |
| Average Diluted Shares Outstanding | -1.77% | -1.90% | -1.09% | -0.23% | 0.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |